<DOC>
	<DOC>NCT01271426</DOC>
	<brief_summary>To determine whether complement factor H (CFH) and age-related maculopathy susceptibility 2 (ARMS2) genotypes have a pharmacogenetic effect on the treatment of polypoidal choroidal vasculopathy (PCV) with ranibizumab.</brief_summary>
	<brief_title>Response to Ranibizumab in Polypoidal Choroidal Vasculopathy (PCV)and SNPs</brief_title>
	<detailed_description />
	<mesh_term>Vascular Diseases</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>Clinical diagnosis of Polypoidal choroidal vasculopathy must have injection of Ranibizumab</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2011</verification_date>
	<keyword>Polypoidal Choroidal Vasculopathy</keyword>
	<keyword>Ranibizumab</keyword>
</DOC>